Pharmaceutical - Antibiotics and Infectious diseases, Pharmaceutical

Filter

Popular Filters

1 to 25 of 220 results

New antifungal as effective as existing drugs with fewer adverse events

New antifungal as effective as existing drugs with fewer adverse events

08-09-2014

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against…

Antibiotics and Infectious diseasesAntifungalsAstellas PharmaBasilea PharmaceuticaInvasive mold diseaseisavuconazoleJapanPharmaceuticalResearchUS Food and Drug AdministrationVoriconazole

Fidaxomicin provides cost benefits in Clostridium difficile against vancomycin for cancer patients

Fidaxomicin provides cost benefits in Clostridium difficile against vancomycin for cancer patients

08-09-2014

Results from a new study have shown overall treatment costs for cancer patients with clostridium difficile…

Antibiotics and Infectious diseasesAstellas PharmaCancerFidaxomicinfidaxomicinMicrobiologyPharmaceuticalResearchVancomycin

FDA accepts Actavis’ NDA for ceftazidime-avibactam

FDA accepts Actavis’ NDA for ceftazidime-avibactam

05-09-2014

Ireland-headquartered generic drugs major Actavis today confirmed that the US Food and Drug Administration…

ActavisAntibiotics and Infectious diseasesceftazidime-avibactamPharmaceuticalRegulationResearchUSA

Debiopharm receives Qualified Infectious Disease designation for Debio 1450 from FDA

Debiopharm receives Qualified Infectious Disease designation for Debio 1450 from FDA

04-09-2014

Swiss independent pharma company Debiopharm has received Qualified Infectious Disease Product designation…

AntibioticsAntibiotics and Infectious diseasesBacterial diseasesDebio 1450DebiopharmMethicillin-resistant Staphylococcus aureusPharmaceuticalRegulationStaphylococcaceaeUSA

Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

04-09-2014

US health care giant Johnson & Johnson will fast-track the development of an Ebola vaccine in response…

Antibiotics and Infectious diseasesBavarian NordicCrucellEbolaJohnson & JohnsonMicrobiologyPharmaceuticalResearch

Sepsis-specific therapies are desperately needed but hard to develop, says GlobalData

Sepsis-specific therapies are desperately needed but hard to develop, says GlobalData

04-09-2014

There is an urgent need to develop sepsis-specific therapies, according to research by consulting firm…

Antibiotics and Infectious diseasesGlobalDataPharmaceuticalResearchSepsis

Tetraphase reports positive oral dosing data in Phase III of eravacycline

Tetraphase reports positive oral dosing data in Phase III of eravacycline

03-09-2014

US pharma company Tetraphase Pharmaceutical has announced positive top-line data from the lead-in portion…

Antibiotics and Infectious diseasesComplicated urinary tract infectionseravacyclineLevofloxacinPharmaceuticalResearchTetraphase PharmaceuticalsUS Food and Drug AdministrationUSA

Novartis signs agreement with TB Alliance for development of its tuberculosis compounds

Novartis signs agreement with TB Alliance for development of its tuberculosis compounds

20-08-2014

Swiss drug major Novartis has signed an exclusive global licensing agreement with the Global Alliance…

Antibiotics and Infectious diseasesNovartisPharmaceuticalResearchSwitzerlandTB AllianceTropical diseasesTuberculosis

AstraZeneca reports positive results from Phase III antibiotic study

AstraZeneca reports positive results from Phase III antibiotic study

19-08-2014

Anglo-Swedish drug major AstraZeneca has achieved positive results from the pivotal Phase III studies…

ActavisAntibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeComplicated intra-abdominal infectionsForest LaboratoriesMedicinePharmaceuticalResearchSerious bacterial infectionsUK

Globavir to seek approval and launch of novel Ebola treatment by year-end

Globavir to seek approval and launch of novel Ebola treatment by year-end

19-08-2014

Privately-held US biotech firm Globavir Biosciences said yesterday that it intends to develop its lead…

Antibiotics and Infectious diseasesGBV006Globavir BiosciencesMarkets & MarketingPharmaceuticalRegulationRest of the WorldTropical diseasesUSA

Boehringer Ingelheim acquires licensing rights for Artilysin technology

Boehringer Ingelheim acquires licensing rights for Artilysin technology

13-08-2014

Artilysin, a new and innovative technological approach in the fight against pathogenic and multi-resistant…

Antibiotics and Infectious diseasesArtilysinBoehringer IngelheimGermanyLicensingLysando AGPharmaceutical

FDA approves The Medicines Company's Orbactiv for use in ABSSSIs

FDA approves The Medicines Company's Orbactiv for use in ABSSSIs

07-08-2014

The Food and Drug Administration has approved The Medicines Company’s Orbactiv (oritavancin) for injection…

Antibiotics and Infectious diseasesOrbactivoritavancinPharmaceuticalRegulationThe Medicines CompanyUSA

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

Novartis' KAE609 effective in uncomplicated malaria patients

Novartis' KAE609 effective in uncomplicated malaria patients

31-07-2014

Swiss drug major Novartis says that results published in the New England Journal of Medicine show that…

Antibiotics and Infectious diseasesJoseph JimenezKAE609NovartisPharmaceuticalPlasmodiumResearchSwitzerland

Durata out-licenses dalbavancin to Angelini for certain territories

Durata out-licenses dalbavancin to Angelini for certain territories

30-07-2014

USA-based Durata Therapeutics says its Dutch subsidiary entered into a license and supply agreement with…

AngeliniAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsEuropeLicensingPharmaceutical

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

15-07-2014

New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered…

Antibiotics and Infectious diseasesFinancialHealthcareNew ZealandNorginePharmaceuticalXifaxan

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

Research shows OPAT drugs should be first used on inpatients to penetrate the market

Research shows OPAT drugs should be first used on inpatients to penetrate the market

11-07-2014

While more than three quarters of surveyed infectious disease specialists are willing to prescribe Durata’s…

AntibioticsAntibiotics and Infectious diseasesDalvanceDecision Resources GrouporitavancinOritavancinPharmaceuticalResearch

Astellas submits NDA for isavuconazole to treat deadly fungal infections

Astellas submits NDA for isavuconazole to treat deadly fungal infections

10-07-2014

Japanese drug major Astellas Pharma has submitted a New Drug Application to the US Food and Drug Administration,…

Antibiotics and Infectious diseasesAntifungal therapiesAspergillosisAstellas PharmaBiologyFungal diseasesImmunologicalsInvasive aspergillosisisavuconazoleJapanMycologyPharmaceuticalRegulationZygomycosis

UK Ministers “must stop unnecessary use of antibiotics”

UK Ministers “must stop unnecessary use of antibiotics”

07-07-2014

A wide-raging report published today by the UK House of Commons Science and Technology Select Committee…

Antibiotics and Infectious diseasesHealthcarePharmaceuticalPoliticsResearchUK

GlobalData says UK fears over antibiotic resistance is

GlobalData says UK fears over antibiotic resistance is "valid conclusion"

04-07-2014

Earlier this week, UK Prime Minister David Cameron revealed the formation of an independent review panel…

Antibiotics and Infectious diseasesEuropePharmaceuticalResearchUSA

UK launches fresh fight against antimicrobial resistance

UK launches fresh fight against antimicrobial resistance

02-07-2014

The UK prime minister David Cameron has said he wants Britain to lead the way in the battle against antimicrobial…

Antibiotics and Infectious diseasesHealthcarePharmaceuticalUK

1 to 25 of 220 results

Back to top